Aurora Spine Corporation

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 13.2M. In comparison, SEMHF has a market cap of 45B. Regarding current trading prices, ASAPF is priced at $0.17, while SEMHF trades at $40.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -16.93, whereas SEMHF's P/E ratio is 18.28. In terms of profitability, ASAPF's ROE is -0.15%, compared to SEMHF's ROE of +0.11%. Regarding short-term risk, ASAPF is less volatile compared to SEMHF. This indicates potentially lower risk in terms of short-term price fluctuations for ASAPF.Check SEMHF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 13.2M. In comparison, RSMDF has a market cap of 26B. Regarding current trading prices, ASAPF is priced at $0.17, while RSMDF trades at $17.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -16.93, whereas RSMDF's P/E ratio is 17.24. In terms of profitability, ASAPF's ROE is -0.15%, compared to RSMDF's ROE of +0.24%. Regarding short-term risk, ASAPF is less volatile compared to RSMDF. This indicates potentially lower risk in terms of short-term price fluctuations for ASAPF.Check RSMDF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 13.2M. In comparison, RYLPF has a market cap of 25.4B. Regarding current trading prices, ASAPF is priced at $0.17, while RYLPF trades at $26.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -16.93, whereas RYLPF's P/E ratio is 23.04. In terms of profitability, ASAPF's ROE is -0.15%, compared to RYLPF's ROE of +0.09%. Regarding short-term risk, ASAPF is more volatile compared to RYLPF. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check RYLPF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 13.2M. In comparison, FUJIY has a market cap of 25B. Regarding current trading prices, ASAPF is priced at $0.17, while FUJIY trades at $10.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -16.93, whereas FUJIY's P/E ratio is 14.59. In terms of profitability, ASAPF's ROE is -0.15%, compared to FUJIY's ROE of +0.08%. Regarding short-term risk, ASAPF is more volatile compared to FUJIY. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check FUJIY's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 13.2M. In comparison, FUJIF has a market cap of 23.9B. Regarding current trading prices, ASAPF is priced at $0.17, while FUJIF trades at $20.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -16.93, whereas FUJIF's P/E ratio is 14.18. In terms of profitability, ASAPF's ROE is -0.15%, compared to FUJIF's ROE of +0.10%. Regarding short-term risk, ASAPF is more volatile compared to FUJIF. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check FUJIF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 13.2M. In comparison, SMMNY has a market cap of 22.7B. Regarding current trading prices, ASAPF is priced at $0.17, while SMMNY trades at $20.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -16.93, whereas SMMNY's P/E ratio is 18.47. In terms of profitability, ASAPF's ROE is -0.15%, compared to SMMNY's ROE of +0.11%. Regarding short-term risk, ASAPF is more volatile compared to SMMNY. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check SMMNY's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 13.2M. In comparison, SONVF has a market cap of 16.4B. Regarding current trading prices, ASAPF is priced at $0.17, while SONVF trades at $275.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -16.93, whereas SONVF's P/E ratio is 23.97. In terms of profitability, ASAPF's ROE is -0.15%, compared to SONVF's ROE of +0.21%. Regarding short-term risk, ASAPF is more volatile compared to SONVF. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check SONVF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 13.2M. In comparison, SONVY has a market cap of 15.8B. Regarding current trading prices, ASAPF is priced at $0.17, while SONVY trades at $52.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -16.93, whereas SONVY's P/E ratio is 23.08. In terms of profitability, ASAPF's ROE is -0.15%, compared to SONVY's ROE of +0.22%. Regarding short-term risk, ASAPF is more volatile compared to SONVY. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check SONVY's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 13.2M. In comparison, CLPBY has a market cap of 14.1B. Regarding current trading prices, ASAPF is priced at $0.17, while CLPBY trades at $6.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -16.93, whereas CLPBY's P/E ratio is 41.59. In terms of profitability, ASAPF's ROE is -0.15%, compared to CLPBY's ROE of +0.14%. Regarding short-term risk, ASAPF is more volatile compared to CLPBY. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check CLPBY's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 13.2M. In comparison, SNNUF has a market cap of 12.7B. Regarding current trading prices, ASAPF is priced at $0.17, while SNNUF trades at $14.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -16.93, whereas SNNUF's P/E ratio is 20.71. In terms of profitability, ASAPF's ROE is -0.15%, compared to SNNUF's ROE of +0.12%. Regarding short-term risk, ASAPF is more volatile compared to SNNUF. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check SNNUF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 13.2M. In comparison, CLPBF has a market cap of 12.5B. Regarding current trading prices, ASAPF is priced at $0.17, while CLPBF trades at $60.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -16.93, whereas CLPBF's P/E ratio is 41.72. In terms of profitability, ASAPF's ROE is -0.15%, compared to CLPBF's ROE of +0.14%. Regarding short-term risk, ASAPF is more volatile compared to CLPBF. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check CLPBF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 13.2M. In comparison, OCPNF has a market cap of 12.3B. Regarding current trading prices, ASAPF is priced at $0.17, while OCPNF trades at $11.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -16.93, whereas OCPNF's P/E ratio is 29.42. In terms of profitability, ASAPF's ROE is -0.15%, compared to OCPNF's ROE of +0.09%. Regarding short-term risk, ASAPF is more volatile compared to OCPNF. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check OCPNF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 13.2M. In comparison, WILYY has a market cap of 8.3B. Regarding current trading prices, ASAPF is priced at $0.17, while WILYY trades at $19.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -16.93, whereas WILYY's P/E ratio is 22.59. In terms of profitability, ASAPF's ROE is -0.15%, compared to WILYY's ROE of +0.16%. Regarding short-term risk, ASAPF is more volatile compared to WILYY. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check WILYY's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 13.2M. In comparison, WILLF has a market cap of 7.5B. Regarding current trading prices, ASAPF is priced at $0.17, while WILLF trades at $35.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -16.93, whereas WILLF's P/E ratio is 20.37. In terms of profitability, ASAPF's ROE is -0.15%, compared to WILLF's ROE of +0.16%. Regarding short-term risk, ASAPF is more volatile compared to WILLF. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check WILLF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 13.2M. In comparison, GNGBY has a market cap of 5.6B. Regarding current trading prices, ASAPF is priced at $0.17, while GNGBY trades at $20.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -16.93, whereas GNGBY's P/E ratio is 22.13. In terms of profitability, ASAPF's ROE is -0.15%, compared to GNGBY's ROE of +0.08%. Regarding short-term risk, ASAPF is more volatile compared to GNGBY. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check GNGBY's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 13.2M. In comparison, GNGBF has a market cap of 5.1B. Regarding current trading prices, ASAPF is priced at $0.17, while GNGBF trades at $20.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -16.93, whereas GNGBF's P/E ratio is 21.56. In terms of profitability, ASAPF's ROE is -0.15%, compared to GNGBF's ROE of +0.08%. Regarding short-term risk, ASAPF is more volatile compared to GNGBF. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check GNGBF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 13.2M. In comparison, CHEOY has a market cap of 4.7B. Regarding current trading prices, ASAPF is priced at $0.17, while CHEOY trades at $36.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -16.93, whereas CHEOY's P/E ratio is 19.14. In terms of profitability, ASAPF's ROE is -0.15%, compared to CHEOY's ROE of +0.18%. Regarding short-term risk, ASAPF is more volatile compared to CHEOY. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check CHEOY's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 13.2M. In comparison, CHEOF has a market cap of 4.7B. Regarding current trading prices, ASAPF is priced at $0.17, while CHEOF trades at $71.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -16.93, whereas CHEOF's P/E ratio is 19.02. In terms of profitability, ASAPF's ROE is -0.15%, compared to CHEOF's ROE of +0.18%. Regarding short-term risk, ASAPF is more volatile compared to CHEOF. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check CHEOF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 13.2M. In comparison, YPHDF has a market cap of 4.7B. Regarding current trading prices, ASAPF is priced at $0.17, while YPHDF trades at $354.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -16.93, whereas YPHDF's P/E ratio is 17.06. In terms of profitability, ASAPF's ROE is -0.15%, compared to YPHDF's ROE of +0.38%. Regarding short-term risk, ASAPF is more volatile compared to YPHDF. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check YPHDF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 13.2M. In comparison, NHNKY has a market cap of 2.9B. Regarding current trading prices, ASAPF is priced at $0.17, while NHNKY trades at $9.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -16.93, whereas NHNKY's P/E ratio is 16.07. In terms of profitability, ASAPF's ROE is -0.15%, compared to NHNKY's ROE of +0.08%. Regarding short-term risk, ASAPF is more volatile compared to NHNKY. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check NHNKY's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 13.2M. In comparison, AMBBY has a market cap of 2.7B. Regarding current trading prices, ASAPF is priced at $0.17, while AMBBY trades at $10.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -16.93, whereas AMBBY's P/E ratio is 36.30. In terms of profitability, ASAPF's ROE is -0.15%, compared to AMBBY's ROE of +0.08%. Regarding short-term risk, ASAPF is more volatile compared to AMBBY. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check AMBBY's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 13.2M. In comparison, AMFPF has a market cap of 2.6B. Regarding current trading prices, ASAPF is priced at $0.17, while AMFPF trades at $12.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -16.93, whereas AMFPF's P/E ratio is 33.36. In terms of profitability, ASAPF's ROE is -0.15%, compared to AMFPF's ROE of +0.07%. Regarding short-term risk, ASAPF is more volatile compared to AMFPF. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check AMFPF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 13.2M. In comparison, AMBFF has a market cap of 2.6B. Regarding current trading prices, ASAPF is priced at $0.17, while AMBFF trades at $9.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -16.93, whereas AMBFF's P/E ratio is 35.36. In terms of profitability, ASAPF's ROE is -0.15%, compared to AMBFF's ROE of +0.08%. Regarding short-term risk, ASAPF is more volatile compared to AMBFF. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check AMBFF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 13.2M. In comparison, NHNKF has a market cap of 2.4B. Regarding current trading prices, ASAPF is priced at $0.17, while NHNKF trades at $15.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -16.93, whereas NHNKF's P/E ratio is 41.86. In terms of profitability, ASAPF's ROE is -0.15%, compared to NHNKF's ROE of +0.08%. Regarding short-term risk, ASAPF is less volatile compared to NHNKF. This indicates potentially lower risk in terms of short-term price fluctuations for ASAPF.Check NHNKF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 13.2M. In comparison, GNNDY has a market cap of 2.2B. Regarding current trading prices, ASAPF is priced at $0.17, while GNNDY trades at $45.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -16.93, whereas GNNDY's P/E ratio is 54.71. In terms of profitability, ASAPF's ROE is -0.15%, compared to GNNDY's ROE of -0.04%. Regarding short-term risk, ASAPF is more volatile compared to GNNDY. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check GNNDY's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 13.2M. In comparison, MCRPF has a market cap of 2.2B. Regarding current trading prices, ASAPF is priced at $0.17, while MCRPF trades at $1.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -16.93, whereas MCRPF's P/E ratio is -12.67. In terms of profitability, ASAPF's ROE is -0.15%, compared to MCRPF's ROE of +0.06%. Regarding short-term risk, ASAPF is more volatile compared to MCRPF. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check MCRPF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 13.2M. In comparison, GGNDF has a market cap of 2.1B. Regarding current trading prices, ASAPF is priced at $0.17, while GGNDF trades at $14.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -16.93, whereas GGNDF's P/E ratio is 52.14. In terms of profitability, ASAPF's ROE is -0.15%, compared to GGNDF's ROE of -0.04%. Regarding short-term risk, ASAPF is more volatile compared to GGNDF. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check GGNDF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 13.2M. In comparison, DRWKF has a market cap of 2.1B. Regarding current trading prices, ASAPF is priced at $0.17, while DRWKF trades at $111.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -16.93, whereas DRWKF's P/E ratio is 11.78. In terms of profitability, ASAPF's ROE is -0.15%, compared to DRWKF's ROE of +0.10%. Regarding short-term risk, ASAPF is more volatile compared to DRWKF. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check DRWKF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 13.2M. In comparison, OSSFF has a market cap of 1.8B. Regarding current trading prices, ASAPF is priced at $0.17, while OSSFF trades at $4.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -16.93, whereas OSSFF's P/E ratio is 20.75. In terms of profitability, ASAPF's ROE is -0.15%, compared to OSSFF's ROE of +0.10%. Regarding short-term risk, ASAPF is less volatile compared to OSSFF. This indicates potentially lower risk in terms of short-term price fluctuations for ASAPF.Check OSSFF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 13.2M. In comparison, DWRKF has a market cap of 1.8B. Regarding current trading prices, ASAPF is priced at $0.17, while DWRKF trades at $543.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -16.93, whereas DWRKF's P/E ratio is 75.94. In terms of profitability, ASAPF's ROE is -0.15%, compared to DWRKF's ROE of N/A. Regarding short-term risk, ASAPF is more volatile compared to DWRKF. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check DWRKF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 13.2M. In comparison, MEDGF has a market cap of 1.7B. Regarding current trading prices, ASAPF is priced at $0.17, while MEDGF trades at $83.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -16.93, whereas MEDGF's P/E ratio is 33.30. In terms of profitability, ASAPF's ROE is -0.15%, compared to MEDGF's ROE of +0.22%. Regarding short-term risk, ASAPF is more volatile compared to MEDGF. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check MEDGF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 13.2M. In comparison, BOEUF has a market cap of 1.6B. Regarding current trading prices, ASAPF is priced at $0.17, while BOEUF trades at $24.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -16.93, whereas BOEUF's P/E ratio is 83.30. In terms of profitability, ASAPF's ROE is -0.15%, compared to BOEUF's ROE of +0.22%. Regarding short-term risk, ASAPF is more volatile compared to BOEUF. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check BOEUF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 13.2M. In comparison, OSSUY has a market cap of 1.6B. Regarding current trading prices, ASAPF is priced at $0.17, while OSSUY trades at $3.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -16.93, whereas OSSUY's P/E ratio is 19.08. In terms of profitability, ASAPF's ROE is -0.15%, compared to OSSUY's ROE of +0.10%. Regarding short-term risk, ASAPF is less volatile compared to OSSUY. This indicates potentially lower risk in terms of short-term price fluctuations for ASAPF.Check OSSUY's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 13.2M. In comparison, DGWPF has a market cap of 1.6B. Regarding current trading prices, ASAPF is priced at $0.17, while DGWPF trades at $83.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -16.93, whereas DGWPF's P/E ratio is 8.76. In terms of profitability, ASAPF's ROE is -0.15%, compared to DGWPF's ROE of +0.10%. Regarding short-term risk, ASAPF is less volatile compared to DGWPF. This indicates potentially lower risk in terms of short-term price fluctuations for ASAPF.Check DGWPF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 13.2M. In comparison, VTRLY has a market cap of 1.5B. Regarding current trading prices, ASAPF is priced at $0.17, while VTRLY trades at $11.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -16.93, whereas VTRLY's P/E ratio is -2.76. In terms of profitability, ASAPF's ROE is -0.15%, compared to VTRLY's ROE of -0.47%. Regarding short-term risk, ASAPF is more volatile compared to VTRLY. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check VTRLY's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 13.2M. In comparison, MDRSF has a market cap of 1.4B. Regarding current trading prices, ASAPF is priced at $0.17, while MDRSF trades at $115.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -16.93, whereas MDRSF's P/E ratio is 135.29. In terms of profitability, ASAPF's ROE is -0.15%, compared to MDRSF's ROE of +0.03%. Regarding short-term risk, ASAPF is more volatile compared to MDRSF. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check MDRSF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 13.2M. In comparison, FDMDF has a market cap of 1.3B. Regarding current trading prices, ASAPF is priced at $0.17, while FDMDF trades at $2.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -16.93, whereas FDMDF's P/E ratio is -7.76. In terms of profitability, ASAPF's ROE is -0.15%, compared to FDMDF's ROE of -9.21%. Regarding short-term risk, ASAPF is less volatile compared to FDMDF. This indicates potentially lower risk in terms of short-term price fluctuations for ASAPF.Check FDMDF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 13.2M. In comparison, ELEAF has a market cap of 1.3B. Regarding current trading prices, ASAPF is priced at $0.17, while ELEAF trades at $15.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -16.93, whereas ELEAF's P/E ratio is 20.69. In terms of profitability, ASAPF's ROE is -0.15%, compared to ELEAF's ROE of +0.17%. Regarding short-term risk, ASAPF is less volatile compared to ELEAF. This indicates potentially lower risk in terms of short-term price fluctuations for ASAPF.Check ELEAF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 13.2M. In comparison, LFTSF has a market cap of 1B. Regarding current trading prices, ASAPF is priced at $0.17, while LFTSF trades at $0.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -16.93, whereas LFTSF's P/E ratio is 23.35. In terms of profitability, ASAPF's ROE is -0.15%, compared to LFTSF's ROE of +0.02%. Regarding short-term risk, ASAPF is more volatile compared to LFTSF. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check LFTSF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 13.2M. In comparison, XVIPF has a market cap of 925.8M. Regarding current trading prices, ASAPF is priced at $0.17, while XVIPF trades at $29.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -16.93, whereas XVIPF's P/E ratio is 117.56. In terms of profitability, ASAPF's ROE is -0.15%, compared to XVIPF's ROE of +0.03%. Regarding short-term risk, ASAPF is less volatile compared to XVIPF. This indicates potentially lower risk in terms of short-term price fluctuations for ASAPF.Check XVIPF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 13.2M. In comparison, BRSYF has a market cap of 674.4M. Regarding current trading prices, ASAPF is priced at $0.17, while BRSYF trades at $16.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -16.93, whereas BRSYF's P/E ratio is 76.55. In terms of profitability, ASAPF's ROE is -0.15%, compared to BRSYF's ROE of +0.12%. Regarding short-term risk, ASAPF is less volatile compared to BRSYF. This indicates potentially lower risk in terms of short-term price fluctuations for ASAPF.Check BRSYF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 13.2M. In comparison, CALZF has a market cap of 635.5M. Regarding current trading prices, ASAPF is priced at $0.17, while CALZF trades at $0.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -16.93, whereas CALZF's P/E ratio is 91.99. In terms of profitability, ASAPF's ROE is -0.15%, compared to CALZF's ROE of +0.12%. Regarding short-term risk, ASAPF is less volatile compared to CALZF. This indicates potentially lower risk in terms of short-term price fluctuations for ASAPF.Check CALZF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 13.2M. In comparison, IOBCF has a market cap of 528.5M. Regarding current trading prices, ASAPF is priced at $0.17, while IOBCF trades at $18.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -16.93, whereas IOBCF's P/E ratio is 36.78. In terms of profitability, ASAPF's ROE is -0.15%, compared to IOBCF's ROE of +0.10%. Regarding short-term risk, ASAPF is less volatile compared to IOBCF. This indicates potentially lower risk in terms of short-term price fluctuations for ASAPF.Check IOBCF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 13.2M. In comparison, AVMR has a market cap of 494.2M. Regarding current trading prices, ASAPF is priced at $0.17, while AVMR trades at $9.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -16.93, whereas AVMR's P/E ratio is -18.34. In terms of profitability, ASAPF's ROE is -0.15%, compared to AVMR's ROE of -0.23%. Regarding short-term risk, ASAPF is more volatile compared to AVMR. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check AVMR's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 13.2M. In comparison, HYBT has a market cap of 361.4M. Regarding current trading prices, ASAPF is priced at $0.17, while HYBT trades at $0.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -16.93, whereas HYBT's P/E ratio is N/A. In terms of profitability, ASAPF's ROE is -0.15%, compared to HYBT's ROE of +0.02%. Regarding short-term risk, ASAPF is more volatile compared to HYBT. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check HYBT's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 13.2M. In comparison, CSSPF has a market cap of 336.4M. Regarding current trading prices, ASAPF is priced at $0.17, while CSSPF trades at $0.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -16.93, whereas CSSPF's P/E ratio is 39.98. In terms of profitability, ASAPF's ROE is -0.15%, compared to CSSPF's ROE of +0.10%. Regarding short-term risk, ASAPF is less volatile compared to CSSPF. This indicates potentially lower risk in terms of short-term price fluctuations for ASAPF.Check CSSPF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 13.2M. In comparison, CLVSF has a market cap of 321.8M. Regarding current trading prices, ASAPF is priced at $0.17, while CLVSF trades at $13.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -16.93, whereas CLVSF's P/E ratio is 22.48. In terms of profitability, ASAPF's ROE is -0.15%, compared to CLVSF's ROE of +0.15%. Regarding short-term risk, ASAPF is less volatile compared to CLVSF. This indicates potentially lower risk in terms of short-term price fluctuations for ASAPF.Check CLVSF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 13.2M. In comparison, CYBQY has a market cap of 294.3M. Regarding current trading prices, ASAPF is priced at $0.17, while CYBQY trades at $1.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -16.93, whereas CYBQY's P/E ratio is -165.00. In terms of profitability, ASAPF's ROE is -0.15%, compared to CYBQY's ROE of +0.01%. Regarding short-term risk, ASAPF is more volatile compared to CYBQY. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check CYBQY's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 13.2M. In comparison, DMTRF has a market cap of 270.5M. Regarding current trading prices, ASAPF is priced at $0.17, while DMTRF trades at $2.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -16.93, whereas DMTRF's P/E ratio is -112.50. In terms of profitability, ASAPF's ROE is -0.15%, compared to DMTRF's ROE of +0.36%. Regarding short-term risk, ASAPF is less volatile compared to DMTRF. This indicates potentially lower risk in terms of short-term price fluctuations for ASAPF.Check DMTRF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 13.2M. In comparison, CYBQF has a market cap of 246.8M. Regarding current trading prices, ASAPF is priced at $0.17, while CYBQF trades at $1.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -16.93, whereas CYBQF's P/E ratio is -185.00. In terms of profitability, ASAPF's ROE is -0.15%, compared to CYBQF's ROE of +0.00%. Regarding short-term risk, ASAPF is less volatile compared to CYBQF. This indicates potentially lower risk in terms of short-term price fluctuations for ASAPF.Check CYBQF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 13.2M. In comparison, EBRCZ has a market cap of 246.1M. Regarding current trading prices, ASAPF is priced at $0.17, while EBRCZ trades at $0.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -16.93, whereas EBRCZ's P/E ratio is -1.50. In terms of profitability, ASAPF's ROE is -0.15%, compared to EBRCZ's ROE of -1.80%. Regarding short-term risk, ASAPF is more volatile compared to EBRCZ. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check EBRCZ's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 13.2M. In comparison, HTLZF has a market cap of 245.1M. Regarding current trading prices, ASAPF is priced at $0.17, while HTLZF trades at $1.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -16.93, whereas HTLZF's P/E ratio is -159.01. In terms of profitability, ASAPF's ROE is -0.15%, compared to HTLZF's ROE of -0.01%. Regarding short-term risk, ASAPF is more volatile compared to HTLZF. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check HTLZF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 13.2M. In comparison, IMPZY has a market cap of 229.3M. Regarding current trading prices, ASAPF is priced at $0.17, while IMPZY trades at $0.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -16.93, whereas IMPZY's P/E ratio is -1.60. In terms of profitability, ASAPF's ROE is -0.15%, compared to IMPZY's ROE of +8.77%. Regarding short-term risk, ASAPF is more volatile compared to IMPZY. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check IMPZY's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 13.2M. In comparison, XVIPY has a market cap of 206M. Regarding current trading prices, ASAPF is priced at $0.17, while XVIPY trades at $6.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -16.93, whereas XVIPY's P/E ratio is N/A. In terms of profitability, ASAPF's ROE is -0.15%, compared to XVIPY's ROE of +0.01%. Regarding short-term risk, ASAPF is more volatile compared to XVIPY. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check XVIPY's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 13.2M. In comparison, VMTHF has a market cap of 186.1M. Regarding current trading prices, ASAPF is priced at $0.17, while VMTHF trades at $0.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -16.93, whereas VMTHF's P/E ratio is -3.01. In terms of profitability, ASAPF's ROE is -0.15%, compared to VMTHF's ROE of -0.21%. Regarding short-term risk, ASAPF is more volatile compared to VMTHF. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check VMTHF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 13.2M. In comparison, DTXMF has a market cap of 180.6M. Regarding current trading prices, ASAPF is priced at $0.17, while DTXMF trades at $0.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -16.93, whereas DTXMF's P/E ratio is -9.52. In terms of profitability, ASAPF's ROE is -0.15%, compared to DTXMF's ROE of -0.74%. Regarding short-term risk, ASAPF is less volatile compared to DTXMF. This indicates potentially lower risk in terms of short-term price fluctuations for ASAPF.Check DTXMF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 13.2M. In comparison, CLLKF has a market cap of 157.5M. Regarding current trading prices, ASAPF is priced at $0.17, while CLLKF trades at $2.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -16.93, whereas CLLKF's P/E ratio is -1.01. In terms of profitability, ASAPF's ROE is -0.15%, compared to CLLKF's ROE of -0.52%. Regarding short-term risk, ASAPF is less volatile compared to CLLKF. This indicates potentially lower risk in terms of short-term price fluctuations for ASAPF.Check CLLKF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 13.2M. In comparison, JMDMF has a market cap of 156.4M. Regarding current trading prices, ASAPF is priced at $0.17, while JMDMF trades at $5.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -16.93, whereas JMDMF's P/E ratio is 83.33. In terms of profitability, ASAPF's ROE is -0.15%, compared to JMDMF's ROE of N/A. Regarding short-term risk, ASAPF is less volatile compared to JMDMF. This indicates potentially lower risk in terms of short-term price fluctuations for ASAPF.Check JMDMF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 13.2M. In comparison, PXMBF has a market cap of 149.9M. Regarding current trading prices, ASAPF is priced at $0.17, while PXMBF trades at $3.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -16.93, whereas PXMBF's P/E ratio is 29.17. In terms of profitability, ASAPF's ROE is -0.15%, compared to PXMBF's ROE of -0.03%. Regarding short-term risk, ASAPF is more volatile compared to PXMBF. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check PXMBF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 13.2M. In comparison, EKDHF has a market cap of 149.3M. Regarding current trading prices, ASAPF is priced at $0.17, while EKDHF trades at $0.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -16.93, whereas EKDHF's P/E ratio is 34.69. In terms of profitability, ASAPF's ROE is -0.15%, compared to EKDHF's ROE of +0.03%. Regarding short-term risk, ASAPF is less volatile compared to EKDHF. This indicates potentially lower risk in terms of short-term price fluctuations for ASAPF.Check EKDHF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 13.2M. In comparison, EAPIF has a market cap of 147.5M. Regarding current trading prices, ASAPF is priced at $0.17, while EAPIF trades at $1.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -16.93, whereas EAPIF's P/E ratio is -0.60. In terms of profitability, ASAPF's ROE is -0.15%, compared to EAPIF's ROE of -0.24%. Regarding short-term risk, ASAPF is less volatile compared to EAPIF. This indicates potentially lower risk in terms of short-term price fluctuations for ASAPF.Check EAPIF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 13.2M. In comparison, BCCOY has a market cap of 145.1M. Regarding current trading prices, ASAPF is priced at $0.17, while BCCOY trades at $0.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -16.93, whereas BCCOY's P/E ratio is -0.92. In terms of profitability, ASAPF's ROE is -0.15%, compared to BCCOY's ROE of -0.51%. Regarding short-term risk, ASAPF is less volatile compared to BCCOY. This indicates potentially lower risk in terms of short-term price fluctuations for ASAPF.Check BCCOY's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 13.2M. In comparison, AMEUF has a market cap of 120.5M. Regarding current trading prices, ASAPF is priced at $0.17, while AMEUF trades at $5.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -16.93, whereas AMEUF's P/E ratio is -1.75. In terms of profitability, ASAPF's ROE is -0.15%, compared to AMEUF's ROE of -1.90%. Regarding short-term risk, ASAPF is less volatile compared to AMEUF. This indicates potentially lower risk in terms of short-term price fluctuations for ASAPF.Check AMEUF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 13.2M. In comparison, SOMNF has a market cap of 98.6M. Regarding current trading prices, ASAPF is priced at $0.17, while SOMNF trades at $0.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -16.93, whereas SOMNF's P/E ratio is -45.00. In terms of profitability, ASAPF's ROE is -0.15%, compared to SOMNF's ROE of -0.05%. Regarding short-term risk, ASAPF is more volatile compared to SOMNF. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check SOMNF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 13.2M. In comparison, RSHUF has a market cap of 91.5M. Regarding current trading prices, ASAPF is priced at $0.17, while RSHUF trades at $0.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -16.93, whereas RSHUF's P/E ratio is -5.81. In terms of profitability, ASAPF's ROE is -0.15%, compared to RSHUF's ROE of -4.12%. Regarding short-term risk, ASAPF is less volatile compared to RSHUF. This indicates potentially lower risk in terms of short-term price fluctuations for ASAPF.Check RSHUF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 13.2M. In comparison, AVHHL has a market cap of 90.1M. Regarding current trading prices, ASAPF is priced at $0.17, while AVHHL trades at $0.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -16.93, whereas AVHHL's P/E ratio is -2.34. In terms of profitability, ASAPF's ROE is -0.15%, compared to AVHHL's ROE of +3.05%. Regarding short-term risk, ASAPF is more volatile compared to AVHHL. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check AVHHL's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 13.2M. In comparison, CKMTF has a market cap of 85.2M. Regarding current trading prices, ASAPF is priced at $0.17, while CKMTF trades at $12.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -16.93, whereas CKMTF's P/E ratio is -3.32. In terms of profitability, ASAPF's ROE is -0.15%, compared to CKMTF's ROE of +2.58%. Regarding short-term risk, ASAPF is more volatile compared to CKMTF. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check CKMTF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 13.2M. In comparison, SNZZF has a market cap of 75M. Regarding current trading prices, ASAPF is priced at $0.17, while SNZZF trades at $0.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -16.93, whereas SNZZF's P/E ratio is -5.30. In terms of profitability, ASAPF's ROE is -0.15%, compared to SNZZF's ROE of -0.38%. Regarding short-term risk, ASAPF is less volatile compared to SNZZF. This indicates potentially lower risk in terms of short-term price fluctuations for ASAPF.Check SNZZF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 13.2M. In comparison, BLOZF has a market cap of 58.2M. Regarding current trading prices, ASAPF is priced at $0.17, while BLOZF trades at $0.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -16.93, whereas BLOZF's P/E ratio is -11.87. In terms of profitability, ASAPF's ROE is -0.15%, compared to BLOZF's ROE of -3.03%. Regarding short-term risk, ASAPF is less volatile compared to BLOZF. This indicates potentially lower risk in terms of short-term price fluctuations for ASAPF.Check BLOZF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 13.2M. In comparison, TLTFF has a market cap of 46.7M. Regarding current trading prices, ASAPF is priced at $0.17, while TLTFF trades at $0.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -16.93, whereas TLTFF's P/E ratio is -16.92. In terms of profitability, ASAPF's ROE is -0.15%, compared to TLTFF's ROE of -3.15%. Regarding short-term risk, ASAPF is less volatile compared to TLTFF. This indicates potentially lower risk in terms of short-term price fluctuations for ASAPF.Check TLTFF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 13.2M. In comparison, BRNHF has a market cap of 42.1M. Regarding current trading prices, ASAPF is priced at $0.17, while BRNHF trades at $0.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -16.93, whereas BRNHF's P/E ratio is -1.33. In terms of profitability, ASAPF's ROE is -0.15%, compared to BRNHF's ROE of -0.09%. Regarding short-term risk, ASAPF is more volatile compared to BRNHF. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check BRNHF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 13.2M. In comparison, NVYTF has a market cap of 34.8M. Regarding current trading prices, ASAPF is priced at $0.17, while NVYTF trades at $0.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -16.93, whereas NVYTF's P/E ratio is -0.86. In terms of profitability, ASAPF's ROE is -0.15%, compared to NVYTF's ROE of -1.22%. Regarding short-term risk, ASAPF is more volatile compared to NVYTF. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check NVYTF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 13.2M. In comparison, RDGL has a market cap of 32.3M. Regarding current trading prices, ASAPF is priced at $0.17, while RDGL trades at $0.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -16.93, whereas RDGL's P/E ratio is -6.53. In terms of profitability, ASAPF's ROE is -0.15%, compared to RDGL's ROE of -1.48%. Regarding short-term risk, ASAPF is less volatile compared to RDGL. This indicates potentially lower risk in terms of short-term price fluctuations for ASAPF.Check RDGL's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 13.2M. In comparison, ACIXF has a market cap of 30.3M. Regarding current trading prices, ASAPF is priced at $0.17, while ACIXF trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -16.93, whereas ACIXF's P/E ratio is -2.70. In terms of profitability, ASAPF's ROE is -0.15%, compared to ACIXF's ROE of -1.06%. Regarding short-term risk, ASAPF is less volatile compared to ACIXF. This indicates potentially lower risk in terms of short-term price fluctuations for ASAPF.Check ACIXF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 13.2M. In comparison, POSC has a market cap of 26.8M. Regarding current trading prices, ASAPF is priced at $0.17, while POSC trades at $1.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -16.93, whereas POSC's P/E ratio is -5.70. In terms of profitability, ASAPF's ROE is -0.15%, compared to POSC's ROE of -7.67%. Regarding short-term risk, ASAPF is more volatile compared to POSC. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check POSC's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 13.2M. In comparison, MKEAF has a market cap of 25.9M. Regarding current trading prices, ASAPF is priced at $0.17, while MKEAF trades at $0.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -16.93, whereas MKEAF's P/E ratio is -4.11. In terms of profitability, ASAPF's ROE is -0.15%, compared to MKEAF's ROE of +0.50%. Regarding short-term risk, ASAPF is more volatile compared to MKEAF. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check MKEAF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 13.2M. In comparison, TCLIF has a market cap of 25.1M. Regarding current trading prices, ASAPF is priced at $0.17, while TCLIF trades at $0.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -16.93, whereas TCLIF's P/E ratio is -4.84. In terms of profitability, ASAPF's ROE is -0.15%, compared to TCLIF's ROE of +2.39%. Regarding short-term risk, ASAPF is less volatile compared to TCLIF. This indicates potentially lower risk in terms of short-term price fluctuations for ASAPF.Check TCLIF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 13.2M. In comparison, PYNKF has a market cap of 24.1M. Regarding current trading prices, ASAPF is priced at $0.17, while PYNKF trades at $0.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -16.93, whereas PYNKF's P/E ratio is 3.83. In terms of profitability, ASAPF's ROE is -0.15%, compared to PYNKF's ROE of -3.36%. Regarding short-term risk, ASAPF is less volatile compared to PYNKF. This indicates potentially lower risk in terms of short-term price fluctuations for ASAPF.Check PYNKF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 13.2M. In comparison, KBBTF has a market cap of 24.1M. Regarding current trading prices, ASAPF is priced at $0.17, while KBBTF trades at $0.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -16.93, whereas KBBTF's P/E ratio is -2.30. In terms of profitability, ASAPF's ROE is -0.15%, compared to KBBTF's ROE of N/A. Regarding short-term risk, ASAPF is more volatile compared to KBBTF. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check KBBTF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 13.2M. In comparison, EMITF has a market cap of 21.3M. Regarding current trading prices, ASAPF is priced at $0.17, while EMITF trades at $1.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -16.93, whereas EMITF's P/E ratio is -7.62. In terms of profitability, ASAPF's ROE is -0.15%, compared to EMITF's ROE of -0.07%. Regarding short-term risk, ASAPF is more volatile compared to EMITF. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check EMITF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 13.2M. In comparison, DIZTF has a market cap of 18M. Regarding current trading prices, ASAPF is priced at $0.17, while DIZTF trades at $0.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -16.93, whereas DIZTF's P/E ratio is -11.16. In terms of profitability, ASAPF's ROE is -0.15%, compared to DIZTF's ROE of -0.52%. Regarding short-term risk, ASAPF is less volatile compared to DIZTF. This indicates potentially lower risk in terms of short-term price fluctuations for ASAPF.Check DIZTF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 13.2M. In comparison, VPTDF has a market cap of 17.8M. Regarding current trading prices, ASAPF is priced at $0.17, while VPTDF trades at $0.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -16.93, whereas VPTDF's P/E ratio is -9.47. In terms of profitability, ASAPF's ROE is -0.15%, compared to VPTDF's ROE of +0.78%. Regarding short-term risk, ASAPF is less volatile compared to VPTDF. This indicates potentially lower risk in terms of short-term price fluctuations for ASAPF.Check VPTDF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 13.2M. In comparison, GTHP has a market cap of 17.6M. Regarding current trading prices, ASAPF is priced at $0.17, while GTHP trades at $0.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -16.93, whereas GTHP's P/E ratio is -5.72. In terms of profitability, ASAPF's ROE is -0.15%, compared to GTHP's ROE of +0.71%. Regarding short-term risk, ASAPF is less volatile compared to GTHP. This indicates potentially lower risk in terms of short-term price fluctuations for ASAPF.Check GTHP's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 13.2M. In comparison, IPDQF has a market cap of 15.9M. Regarding current trading prices, ASAPF is priced at $0.17, while IPDQF trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -16.93, whereas IPDQF's P/E ratio is -0.78. In terms of profitability, ASAPF's ROE is -0.15%, compared to IPDQF's ROE of -1.65%. Regarding short-term risk, ASAPF is more volatile compared to IPDQF. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check IPDQF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 13.2M. In comparison, MDXHF has a market cap of 14.4M. Regarding current trading prices, ASAPF is priced at $0.17, while MDXHF trades at $0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -16.93, whereas MDXHF's P/E ratio is -4.40. In terms of profitability, ASAPF's ROE is -0.15%, compared to MDXHF's ROE of +0.66%. Regarding short-term risk, ASAPF is more volatile compared to MDXHF. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check MDXHF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 13.2M. In comparison, TMDIF has a market cap of 13.9M. Regarding current trading prices, ASAPF is priced at $0.17, while TMDIF trades at $0.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -16.93, whereas TMDIF's P/E ratio is -0.65. In terms of profitability, ASAPF's ROE is -0.15%, compared to TMDIF's ROE of +8.70%. Regarding short-term risk, ASAPF is less volatile compared to TMDIF. This indicates potentially lower risk in terms of short-term price fluctuations for ASAPF.Check TMDIF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 13.2M. In comparison, ATBPF has a market cap of 11.4M. Regarding current trading prices, ASAPF is priced at $0.17, while ATBPF trades at $0.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -16.93, whereas ATBPF's P/E ratio is -0.86. In terms of profitability, ASAPF's ROE is -0.15%, compared to ATBPF's ROE of -0.40%. Regarding short-term risk, ASAPF is less volatile compared to ATBPF. This indicates potentially lower risk in terms of short-term price fluctuations for ASAPF.Check ATBPF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 13.2M. In comparison, ALRTF has a market cap of 11.4M. Regarding current trading prices, ASAPF is priced at $0.17, while ALRTF trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -16.93, whereas ALRTF's P/E ratio is -0.44. In terms of profitability, ASAPF's ROE is -0.15%, compared to ALRTF's ROE of +0.52%. Regarding short-term risk, ASAPF is less volatile compared to ALRTF. This indicates potentially lower risk in terms of short-term price fluctuations for ASAPF.Check ALRTF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 13.2M. In comparison, LXXGF has a market cap of 11.3M. Regarding current trading prices, ASAPF is priced at $0.17, while LXXGF trades at $0.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -16.93, whereas LXXGF's P/E ratio is -0.85. In terms of profitability, ASAPF's ROE is -0.15%, compared to LXXGF's ROE of -1.23%. Regarding short-term risk, ASAPF is more volatile compared to LXXGF. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check LXXGF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 13.2M. In comparison, PLLWF has a market cap of 8M. Regarding current trading prices, ASAPF is priced at $0.17, while PLLWF trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -16.93, whereas PLLWF's P/E ratio is -0.66. In terms of profitability, ASAPF's ROE is -0.15%, compared to PLLWF's ROE of -0.99%. Regarding short-term risk, ASAPF is less volatile compared to PLLWF. This indicates potentially lower risk in terms of short-term price fluctuations for ASAPF.Check PLLWF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 13.2M. In comparison, PMEDF has a market cap of 6.3M. Regarding current trading prices, ASAPF is priced at $0.17, while PMEDF trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -16.93, whereas PMEDF's P/E ratio is -3.07. In terms of profitability, ASAPF's ROE is -0.15%, compared to PMEDF's ROE of +1.24%. Regarding short-term risk, ASAPF is less volatile compared to PMEDF. This indicates potentially lower risk in terms of short-term price fluctuations for ASAPF.Check PMEDF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 13.2M. In comparison, BIEL has a market cap of 6.3M. Regarding current trading prices, ASAPF is priced at $0.17, while BIEL trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -16.93, whereas BIEL's P/E ratio is N/A. In terms of profitability, ASAPF's ROE is -0.15%, compared to BIEL's ROE of +0.05%. Regarding short-term risk, ASAPF is less volatile compared to BIEL. This indicates potentially lower risk in terms of short-term price fluctuations for ASAPF.Check BIEL's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 13.2M. In comparison, QLIS has a market cap of 5.5M. Regarding current trading prices, ASAPF is priced at $0.17, while QLIS trades at $0.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -16.93, whereas QLIS's P/E ratio is 2.22. In terms of profitability, ASAPF's ROE is -0.15%, compared to QLIS's ROE of -0.15%. Regarding short-term risk, ASAPF is more volatile compared to QLIS. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check QLIS's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 13.2M. In comparison, RHNMF has a market cap of 5.4M. Regarding current trading prices, ASAPF is priced at $0.17, while RHNMF trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -16.93, whereas RHNMF's P/E ratio is -0.95. In terms of profitability, ASAPF's ROE is -0.15%, compared to RHNMF's ROE of +15.91%. Regarding short-term risk, ASAPF is less volatile compared to RHNMF. This indicates potentially lower risk in terms of short-term price fluctuations for ASAPF.Check RHNMF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 13.2M. In comparison, ADMT has a market cap of 4.7M. Regarding current trading prices, ASAPF is priced at $0.17, while ADMT trades at $0.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -16.93, whereas ADMT's P/E ratio is -6.90. In terms of profitability, ASAPF's ROE is -0.15%, compared to ADMT's ROE of -0.01%. Regarding short-term risk, ASAPF is less volatile compared to ADMT. This indicates potentially lower risk in terms of short-term price fluctuations for ASAPF.Check ADMT's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 13.2M. In comparison, USAQ has a market cap of 4.1M. Regarding current trading prices, ASAPF is priced at $0.17, while USAQ trades at $0.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -16.93, whereas USAQ's P/E ratio is 11.17. In terms of profitability, ASAPF's ROE is -0.15%, compared to USAQ's ROE of +0.92%. Regarding short-term risk, ASAPF is less volatile compared to USAQ. This indicates potentially lower risk in terms of short-term price fluctuations for ASAPF.Check USAQ's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 13.2M. In comparison, ELXMF has a market cap of 4.1M. Regarding current trading prices, ASAPF is priced at $0.17, while ELXMF trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -16.93, whereas ELXMF's P/E ratio is -0.72. In terms of profitability, ASAPF's ROE is -0.15%, compared to ELXMF's ROE of -0.40%. Regarding short-term risk, ASAPF is less volatile compared to ELXMF. This indicates potentially lower risk in terms of short-term price fluctuations for ASAPF.Check ELXMF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 13.2M. In comparison, RMSL has a market cap of 3.9M. Regarding current trading prices, ASAPF is priced at $0.17, while RMSL trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -16.93, whereas RMSL's P/E ratio is 0.23. In terms of profitability, ASAPF's ROE is -0.15%, compared to RMSL's ROE of -17961324.55%. Regarding short-term risk, ASAPF is less volatile compared to RMSL. This indicates potentially lower risk in terms of short-term price fluctuations for ASAPF.Check RMSL's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 13.2M. In comparison, VANIW has a market cap of 3.4M. Regarding current trading prices, ASAPF is priced at $0.17, while VANIW trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -16.93, whereas VANIW's P/E ratio is N/A. In terms of profitability, ASAPF's ROE is -0.15%, compared to VANIW's ROE of -2.64%. Regarding short-term risk, ASAPF is less volatile compared to VANIW. This indicates potentially lower risk in terms of short-term price fluctuations for ASAPF.Check VANIW's competition here